Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of STX107 in Adults With Fragile X Syndrome

NCT01325740 is registered in ClinicalTrials.gov with Seaside Therapeutics, Inc. as lead sponsor.

NCT NCT01325740
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01325740 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of STX107 in Adults With Fragile X Syndrome
Lead sponsor
Seaside Therapeutics, Inc.
Phase
Phase 2
Overall status
Suspended
Start date
May 31, 2011
Completion date
September 30, 2013
Enrollment
16 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

fragile x syndrome